Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exosome injection for cesarean scar defect and IVF outcome
IRCT20091012002576N46Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Aug 2024
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial of endothelial progenitor cell-derived exosomes in Caesarean scar defect (CSD) and female infertility (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Biochemical pregnancy. Started Aug 2024; status: completed.
02
Drugs
endothelial progenitor cell-derived exosomes
03
Conditions
Caesarean scar defect (CSD)female infertility
Beyond the preview
Go deeper on IRCT20091012002576N46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20091012002576N46.